Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nature's Health receives warning

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Nature's Health Co. that at least 18 of its products marketed as supplements are unapproved drugs due to unlawful disease treatment and prevention claims that "were too numerous to list." It also warns the Salt Lake City firm that several of the products, including Cardiac Balance I to control arrhythmia and Flavescent for autoimmune system disease symptom relief, are misbranded because they are offered for conditions that are not self-diagnosable or self-treatable. According to the Sept. 21 letter, the products advertised at 1www.nature-s-health.com were not recognized as safe and effective and, therefore, are new drugs

You may also be interested in...



Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US

Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.

EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care

Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.

Polpharma Biologics Rebrands As New Warsaw Site Is Validated

As it gears up to begin production at its new clinical and commercial manufacturing site in Warsaw, Polpharma Biologics has announced a new logo and corporate message to mark a year of “significant growth.”

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel